Conflict of Interest
Janssen, Johnson & Johnson,, IBD
S.S. reports speaker/consultancy fees from AbbVie, Advanced Molecular Transport, Amgen, Bristol Myers Squibb [BMS], Boehringer Ingelheim, Falk, Ferring Pharmaceuticals, Galapagos/Gilead, Genentech/Roche, Janssen, Merck/MSD, Pfizer, Prometheus and Takeda. B.G.F. reports grants and personal fees from AbbVie, Amgen, AstraZeneca, BMS, Janssen Biotech/Centocor, Johnson & Johnson/Janssen, Pfizer, Receptos and Takeda; personal fees from Ablynx, ActoGeniX, AdMIRx Inc., Akebia Therapeutics Inc., Allergan, Atlantic Pharma, Avaxia Biologics Inc., Avir Pharma, Baxter Healthcare Corporation, Biogen Idec, BiomX Israel, Boehringer Ingelheim, Boston Pharmaceuticals, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring Pharmaceuticals, Galapagos, Genentech/Roche, gIcare Pharma, Gilead, Given Imaging, Gossamer Pharma, GSK, Inception IBD Inc., Ironwood, Japan Tobacco Inc., Kyowa Hakko Kirin Co. Ltd, Lexicon, Lilly, Lycera Biotech, Merck, Mesoblast Pharma, Millennium Pharmaceuticals, Nestlé, Nextbiotix, Novartis, Novo Nordisk, Par’Immune, Progenity, Prometheus Therapeutics and Diagnostics, Protagonist, Qu Biologics, Salix Pharmaceuticals, Shire, Sienna Biologics, Sigmoid Pharma, Synergy Pharma, Teva Pharmaceuticals, TiGenix, Tillotts, UCB, Vertex, VHsquared, Vivelix Pharmaceuticals, Wyeth, Zealand Pharma and Zyngenia; and is the Senior Scientific Director of Alimentiv Inc. and a Professor of Medicine at Western University. L.P.B. reports personal fees from AbbVie, Allergan, Amgen, Arena, Biogen, BMS, Celgene, Celltrion, Enthera, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, Index Pharmaceuticals, Inotrem, Janssen, Lilly, MSD, Mylan, Norgine, OSE Immunotherapeutics, Pandion Therapeutics, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Theravance, Thermo Fisher, Tillotts, Viaris, and Vifor; grants from AbbVie, Fresenius Kabi, MSD and Takeda; and stock options from CTMA. S.V. reports grants from AbbVie, Galapagos, Johnson & Johnson, Pfizer and Takeda, and consultancy fees from AbbVie, Abivax, Arena Pharmaceuticals, Avaxia, Boehringer Ingelheim, Celgene, Dr Falk Pharma, Ferring Pharmaceuticals, Galapagos, Genentech/Roche, Gilead, GSK, Hospira, Janssen, Mundipharma, MSD, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Takeda, Theravance and Tillotts Pharma AG. M.F., K.H. and A.O. are employees and shareholders of Galapagos NV. H.P. was an employee and shareholder of Galapagos NV at the time of the study. P.D. is an employee of Cytel Health Canada, which received funding from Galapagos NV to conduct the analysis. S.D. reports personal fees from AbbVie, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals, Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc. and Vifor.